Investors Purchase Large Volume of X4 Pharmaceuticals Call Options (NASDAQ:XFOR)

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) saw some unusual options trading activity on Friday. Stock investors bought 2,518 call options on the stock. This represents an increase of 119% compared to the typical daily volume of 1,148 call options.

X4 Pharmaceuticals Stock Down 3.1%

XFOR stock traded down $0.10 during midday trading on Friday, hitting $3.25. The company’s stock had a trading volume of 102,141 shares, compared to its average volume of 640,043. X4 Pharmaceuticals has a twelve month low of $2.43 and a twelve month high of $4.83. The stock has a market capitalization of $322.72 million, a P/E ratio of -2.74 and a beta of 0.46. The company’s fifty day moving average price is $3.34 and its 200 day moving average price is $3.80. The company has a debt-to-equity ratio of 0.49, a current ratio of 11.30 and a quick ratio of 11.02.

X4 Pharmaceuticals (NASDAQ:XFOR) last announced its quarterly earnings results on Thursday, August 6th. The company reported ($0.13) EPS for the quarter, beating analysts’ consensus estimates of ($0.18) by $0.05. The firm had revenue of $8.81 million for the quarter, compared to analyst estimates of $2.42 million. X4 Pharmaceuticals had a negative return on equity of 63.05% and a negative net margin of 568.80%. As a group, equities research analysts predict that X4 Pharmaceuticals will post -0.67 EPS for the current year.

Insiders Place Their Bets

In other X4 Pharmaceuticals news, CFO David Kirske sold 11,767 shares of the stock in a transaction on Thursday, October 1st. The stock was sold at an average price of $2.86, for a total transaction of $33,653.62. Following the sale, the chief financial officer owned 155,983 shares of the company’s stock, valued at approximately $446,111.38. This trade represents a 7.01% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, President John Volpone sold 24,576 shares of the firm’s stock in a transaction that occurred on Wednesday, August 12th. The stock was sold at an average price of $4.44, for a total transaction of $109,117.44. Following the transaction, the president directly owned 265,305 shares of the company’s stock, valued at $1,177,954.20. This represents a 8.48% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 83,779 shares of company stock worth $353,387. 1.13% of the stock is currently owned by company insiders.

Institutional Trading of X4 Pharmaceuticals

Large investors have recently modified their holdings of the company. WINTON GROUP Ltd raised its holdings in X4 Pharmaceuticals by 35.8% during the second quarter. WINTON GROUP Ltd now owns 14,400 shares of the company’s stock valued at $67,000 after acquiring an additional 3,800 shares during the period. Pettinga Financial Advisors LLC bought a new position in shares of X4 Pharmaceuticals in the 2nd quarter valued at about $47,000. SummitTX Capital L.P. purchased a new position in X4 Pharmaceuticals during the first quarter worth $46,000. AXQ Capital LP bought a new position in shares of X4 Pharmaceuticals during the second quarter valued at approximately $107,000. Finally, Wellington Management Group LLP bought a new stake in shares of X4 Pharmaceuticals during the second quarter worth $242,000. Institutional investors own 72.03% of the company’s stock.

Analyst Ratings Changes

A number of research firms have commented on XFOR. Wells Fargo & Company initiated coverage on X4 Pharmaceuticals in a report on Friday, July 10th. They issued an “overweight” rating and a $11.00 target price for the company. Weiss Ratings cut shares of X4 Pharmaceuticals from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, October 20th. Four investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, X4 Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average target price of $11.25.

X4 Pharmaceuticals Company Profile

X4 Pharmaceuticals, Inc is a biotechnology company focused on developing and commercializing therapies for rare diseases caused by disorders of the immune system. The company’s research centers on the CXCR4 pathway, which plays a role in the movement and function of immune cells.

X4’s lead product, XOLREMDI (mavorixafor), is an oral CXCR4 antagonist approved by the U.S. Food and Drug Administration for use in patients aged 12 and older with WHIM syndrome, a rare primary immunodeficiency disorder.